Matches in SemOpenAlex for { <https://semopenalex.org/work/W4292866351> ?p ?o ?g. }
- W4292866351 abstract "Abstract Booster doses for the ongoing COVID-19 pandemic are under consideration in many countries. We report a three-month follow-up of 700 participants in a fourth vaccine dose study, comparing BNT162b2 and mRNA1273, administered four months after a third BNT162b2 dose. Waning of the immune response was evident during follow-up, with an 11% (ß=0.89, 95% CI, 0.88–0.9) and 21% (ß=0.79, 95% CI, 0.76–0.82) multiplicative decay per week of IgG and neutralizing antibodies, respectively, in the mRNA1273 group, and of 14% (ß=0.86, 95% CI, 0.86–0.87) and 26% (ß=0.74, 95% CI, 0.72–0.76), respectively, in the BNT162b2 group. Direct neutralization of Omicron variants was low relative to ancestral strains. Cumulatively over the study period, both vaccines showed little efficacy against infection but were highly efficacious against substantial disease [89% [(IRR 0.11, 95% CI, 0.02–0.37) and 71% (IRR 0.29, 95% CI, 0.13–0.57) for mRNA1273 and BNT162b2, respectively]. These results are informative for further boosting policy-making." @default.
- W4292866351 created "2022-08-24" @default.
- W4292866351 creator A5000778248 @default.
- W4292866351 creator A5002193307 @default.
- W4292866351 creator A5002704057 @default.
- W4292866351 creator A5004609370 @default.
- W4292866351 creator A5004886688 @default.
- W4292866351 creator A5011801479 @default.
- W4292866351 creator A5013178591 @default.
- W4292866351 creator A5018804854 @default.
- W4292866351 creator A5022884552 @default.
- W4292866351 creator A5031183927 @default.
- W4292866351 creator A5033290213 @default.
- W4292866351 creator A5068311689 @default.
- W4292866351 creator A5080128827 @default.
- W4292866351 creator A5085626163 @default.
- W4292866351 creator A5090111671 @default.
- W4292866351 creator A5091779604 @default.
- W4292866351 date "2022-08-11" @default.
- W4292866351 modified "2023-10-18" @default.
- W4292866351 title "Immune Response and Clinical Outcomes of BNT162b2 and mRNA1273 Fourth Dose COVID-19 Vaccines; Three Months Follow-up" @default.
- W4292866351 cites W3111255098 @default.
- W4292866351 cites W3131688063 @default.
- W4292866351 cites W3133128009 @default.
- W4292866351 cites W3158276912 @default.
- W4292866351 cites W3176479223 @default.
- W4292866351 cites W3180361036 @default.
- W4292866351 cites W3184172540 @default.
- W4292866351 cites W3196397911 @default.
- W4292866351 cites W3198831432 @default.
- W4292866351 cites W3201177512 @default.
- W4292866351 cites W3208126540 @default.
- W4292866351 cites W3210126657 @default.
- W4292866351 cites W3211197905 @default.
- W4292866351 cites W3215466831 @default.
- W4292866351 cites W4200066927 @default.
- W4292866351 cites W4200236595 @default.
- W4292866351 cites W4205170082 @default.
- W4292866351 cites W4205483821 @default.
- W4292866351 cites W4210450230 @default.
- W4292866351 cites W4220673385 @default.
- W4292866351 cites W4220770600 @default.
- W4292866351 cites W4220988150 @default.
- W4292866351 cites W4224233099 @default.
- W4292866351 cites W4224319009 @default.
- W4292866351 cites W4224816971 @default.
- W4292866351 cites W4225505755 @default.
- W4292866351 cites W4225854071 @default.
- W4292866351 cites W4226050536 @default.
- W4292866351 cites W4226229183 @default.
- W4292866351 cites W4226376477 @default.
- W4292866351 cites W4229043677 @default.
- W4292866351 cites W4229367228 @default.
- W4292866351 cites W4280558095 @default.
- W4292866351 cites W4281648214 @default.
- W4292866351 cites W4281827985 @default.
- W4292866351 doi "https://doi.org/10.21203/rs.3.rs-1946528/v1" @default.
- W4292866351 hasPublicationYear "2022" @default.
- W4292866351 type Work @default.
- W4292866351 citedByCount "0" @default.
- W4292866351 crossrefType "posted-content" @default.
- W4292866351 hasAuthorship W4292866351A5000778248 @default.
- W4292866351 hasAuthorship W4292866351A5002193307 @default.
- W4292866351 hasAuthorship W4292866351A5002704057 @default.
- W4292866351 hasAuthorship W4292866351A5004609370 @default.
- W4292866351 hasAuthorship W4292866351A5004886688 @default.
- W4292866351 hasAuthorship W4292866351A5011801479 @default.
- W4292866351 hasAuthorship W4292866351A5013178591 @default.
- W4292866351 hasAuthorship W4292866351A5018804854 @default.
- W4292866351 hasAuthorship W4292866351A5022884552 @default.
- W4292866351 hasAuthorship W4292866351A5031183927 @default.
- W4292866351 hasAuthorship W4292866351A5033290213 @default.
- W4292866351 hasAuthorship W4292866351A5068311689 @default.
- W4292866351 hasAuthorship W4292866351A5080128827 @default.
- W4292866351 hasAuthorship W4292866351A5085626163 @default.
- W4292866351 hasAuthorship W4292866351A5090111671 @default.
- W4292866351 hasAuthorship W4292866351A5091779604 @default.
- W4292866351 hasBestOaLocation W42928663511 @default.
- W4292866351 hasConcept C116675565 @default.
- W4292866351 hasConcept C12590561 @default.
- W4292866351 hasConcept C126322002 @default.
- W4292866351 hasConcept C159047783 @default.
- W4292866351 hasConcept C159654299 @default.
- W4292866351 hasConcept C203014093 @default.
- W4292866351 hasConcept C2779134260 @default.
- W4292866351 hasConcept C2780801004 @default.
- W4292866351 hasConcept C3006700255 @default.
- W4292866351 hasConcept C3007834351 @default.
- W4292866351 hasConcept C3008058167 @default.
- W4292866351 hasConcept C3018913218 @default.
- W4292866351 hasConcept C524204448 @default.
- W4292866351 hasConcept C71924100 @default.
- W4292866351 hasConcept C8891405 @default.
- W4292866351 hasConcept C89623803 @default.
- W4292866351 hasConceptScore W4292866351C116675565 @default.
- W4292866351 hasConceptScore W4292866351C12590561 @default.
- W4292866351 hasConceptScore W4292866351C126322002 @default.
- W4292866351 hasConceptScore W4292866351C159047783 @default.
- W4292866351 hasConceptScore W4292866351C159654299 @default.
- W4292866351 hasConceptScore W4292866351C203014093 @default.